Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07037901 is registered in ClinicalTrials.gov with Inmagene LLC as lead sponsor.

NCT NCT07037901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Inmagene LLC
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2025
Completion date
August 31, 2028
Enrollment
405 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis eczema, eczema